This license will enable Nutrasource hold, distribute, and conduct clinical research studies on controlled substances, among other things.
Nutrasource Pharmaceutical and Nutraceutical Services (Guelph, ON) received a Controlled Drugs and Substances Dealer’s License from Health Canada. This is the first license to be obtained by a third-party, natural-products-focused CRO in Canada. This license will enable Nutrasource hold, distribute, and conduct clinical research studies on controlled substances, among other things.
“With fully developed study protocols, safe storage and management, as well as an experienced QPIC (qualified person in charge) recognized by Health Canada’s Office of Controlled Substances, Nutrasource is ready for controlled drug and substances projects,” said Ana Samborski, pharmacy manager, Nutrasource, in a press release.
Nutrasource’s clients will now have the opportunity to conduct early-stage clinical studies, including bioavailability/bioequivalence) studies, proof of concept studies, and efficacy trials with controlled substances in Canada.
“This license is an excellent and logical extension of our institution-wide cannabis research license obtained earlier this year. Botanicals and their derivatives continue to be a key focus and these licenses enhance our position further in the nutra to pharma services pathway,” said William Rowe, Nutrasource president and CEO.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.